Keele Research Repository

Article

Oswald, AJ, Symeonides, SN, Wheatley, D, Chan, S, Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, McAdam, K, Schmid, P, Waters, S, Poole, C, Twelves, C, Perren, T, Bartlett, J, Piper, T, Chisholm, EM, Welsh, M, Hill, R, Hopcroft, LEM, Barrett-Lee, P and Cameron, DA (2023) Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study. Breast Cancer Research and Treatment.

Earl, HM, Hiller, H, Vallier, A-L, Bowden, SJ, Jordan, SD, Blows, F, Munro, A, Bathers, S, Grieve, R, Spooner, DA, Agrawal, R, Fernando, I, Brunt, AM, O'Reilly, SM, Crawford, SM, Rea, DW, Simmonds, P, Mansi, JL, Stanley, A, McAdam, K, Foster, L, Leonard, RCF, Twelves, CJ, Cameron, D, Bartlett, JMS, Pharoah, P, Provenzano, E, Caldas, C and Poole, CJ (2012) Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials. British Journal of Cancer, 107 (8). pp. 1257-1267.